
    
      Phase1 study of GSK1325760A

      - A double blind, single center, randomised, placebo-controlled, partially crossover, single
      dose study to investigate the safety, tolerability, pharmacokinetics and to assess the effect
      of food on pharmacokinetics of ascending oral doses of GSK1325760A in healthy Japanese male
      subject -
    
  